Demirelli, Selami
(Department of Cardiology, Erzurum Regional Training and Research Hospital)
Karakelleoglu, Sule (Department of Cardiology, Faculty of Medicine, Ataturk University) Gundogdu, Fuat (Department of Cardiology, Faculty of Medicine, Ataturk University) Tas, Muhammed Hakan (Department of Cardiology, Faculty of Medicine, Ataturk University) Kaya, Ahmet (Department of Cardiology, Faculty of Medicine Ordu University) Duman, Hakan (Department of Cardiology, Rize State Hospital) Degirmenci, Husnu (Department of Cardiology, Erzurum Palandoken State Hospital) Hamur, Hikmet (Department of Cardiology, Mengucek Gazi Regional Training and Research Hospital) Simsek, Ziya (Department of Cardiology, Faculty of Medicine, Ataturk University) |
1 | American Heart Association. 1999 heart and stroke statistical update. Chicago: American Heart Association;1999. |
2 | Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267-74. DOI |
3 | Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 1998;30:A112. |
4 | Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21:128-35. DOI |
5 | Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000;342:1163-70. DOI |
6 | Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006;98: 14J-8J. |
7 | Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007;120:79-84. DOI |
8 | Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 1991;4:909-12. DOI |
9 | Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9. DOI |
10 | Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8. DOI |
11 | White HD, French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2003;42:1917-20. DOI |
12 | Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40:437-45. DOI |
13 | Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20:1447-54. DOI |
14 | Banach M. The role of trimetazidine in the treatment of heart diseases. Ponzan, Poland: Termedia Publishing House;2006. p.52-6. |
15 | Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002;45:69-72. DOI |
16 | Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007;7:143-50. DOI |
17 | Lopez N, Varo N, Diez J, Fortuno MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007;75:536-45. DOI |
18 | Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 2002;11:615-29. DOI |
19 | Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8. DOI |